Obsessive-Compulsive Disorder (OCD) Clinical Trial
Official title:
The Effect of Deep Brain Stimulation (DBS) in Treatment-resistant Obsessive-compulsive Disorder (TR-OCD)
The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) implantation targeting the anteromedial region of subthalamic nucleus (amSTN), or nucleus accumbens (NAc), or bed nucleus of the stria terminalis (BNST), or ventral capsule/ventral striatum (VC/VS), or the ventral anterior limb of the internal capsule (vALIC) in patients with treatment-resistant obsessive-compulsive disorder (TR-OCD).
At least 40-60% of people with obsessive-compulsive disorder (OCD) continue to have symptoms after drug treatment. There is still a lack of effective therapies for TR-OCD. In a comprehensive survey of diverse neuromodulation therapies, targeting specific nuclei with DBS has the most potential for OCD with apparent symptoms. The stimulation targets of DBS for patients with TR-OCD include vALIC, BNST, amSTN, VC/VS, and NAc. For the target site of each individual, it depends on the individualized evaluation results made by the study team. Although DBS is effective and tolerable and has the potential to improve the lives of many patients with TR-OCD, evidence remains limited. To explore its effectiveness, this project plans to conduct DBS-targeted vALIC, BNST, amSTN, VC/ VS, or NAc on RT-OCD patients. Another goal of this program is to study the neuronal activity of the vALIC, BNST, amSTN, VC/VS, and NAc, respectively. At the same time, some subjects are presented with a task involving an unexpected reward. This separate study is an option and will not affect current study participation. Some participants will also be invited to join a related study that involves positron emission tomography (PET) scanning to determine how the stimulation changes activity in the brain. Participation in the separate PET study is optional and will not affect current study participation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01949753 -
Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder
|
Phase 2 | |
| Completed |
NCT02267629 -
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
|
Phase 2 | |
| Recruiting |
NCT04042038 -
Neural Predictors and Neural Changes Associated With Cognitive Behavior Therapy for Obssesive Compulsive Disorder
|
N/A | |
| Completed |
NCT02867449 -
Metacognitive Therapy for Obsessive-Compulsive Disorder
|
N/A | |
| Completed |
NCT01368510 -
Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder
|
N/A | |
| Not yet recruiting |
NCT05422469 -
OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial
|
N/A | |
| Active, not recruiting |
NCT03300947 -
Psilocybin for Treatment of Obsessive Compulsive Disorder
|
Phase 1 | |
| Recruiting |
NCT02773082 -
Reclaim™ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)
|
N/A | |
| Completed |
NCT03605316 -
Deep Electrical Neuromodulation in Obsessive-compulsive Disorder
|